KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $17.8 million.

  • Halozyme Therapeutics' Amortizatization of Intangibles changed 0.0% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year change of 0.14%. This contributed to the annual value of $71.0 million for FY2024, which is 369.24% down from last year.
  • Halozyme Therapeutics' Amortizatization of Intangibles amounted to $17.8 million in Q3 2025, which was down 0.0% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Amortizatization of Intangibles ranged from a high of $27.2 million in Q3 2022 and a low of $741000.0 during Q1 2021
  • Its 5-year average for Amortizatization of Intangibles is $14.3 million, with a median of $17.8 million in 2023.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 7869.47% in 2021, then surged by 173676.62% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Amortizatization of Intangibles (Quarter) stood at $968000.0 in 2021, then soared by 370.25% to $4.6 million in 2022, then soared by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then changed by 0.0% to $17.8 million in 2025.
  • Its last three reported values are $17.8 million in Q3 2025, $17.8 million for Q2 2025, and $17.8 million during Q1 2025.